Literature DB >> 26497867

Subacute hepatic necrosis mimicking veno-occlusive disease in a patient with HFE H63D homozygosity after allogeneic hematopoietic cell transplantation with busulfan conditioning.

Sylvia Chen, James Dane Osborn, Xinjian Chen, Michael W Boyer, George B McDonald, Gerhard Carl Hildebrandt.   

Abstract

Busulfan is a commonly used chemotherapeutic agent in myeloablative conditioning regimens for allogeneic hematopoietic cell transplantation (allo-HCT). It has been associated with sinusoidal-obstructive syndrome(SOS) as a life-threatening complication of myeloablative allo-HCT, yet it has not been found to cause severe hepatocellular injury, even in cases of significant accidental overdose.We report the case of a 31-year-old male with a history of high-risk myelodysplastic syndrome transitioning to acute myeloid leukemia, who in complete remission underwent allo-HCT using myeloablative busulfanfludarabine conditioning, and who developed hepatic failure. While he met clinical criteria for SOS and was treated with defibrotide,liver biopsy demonstrated severe subacute hepatic necrosis and lacked characteristics of SOS. Further evaluation revealed that the patient was homozygous for the HFE H63D gene mutation, associated with hereditary hemochromatosis.Both Busulfan and iron overload related to HFE H63D homozygosity can cause oxidative stress resulting in cellular injury, and the cumulative effects of these risk factors are possibly responsible for the severe hepatocellular injury in this case, making our patient the first-known case of subacute hepatic necrosis related to busulfan administration.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26497867     DOI: 10.1007/s12185-015-1878-x

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  10 in total

1.  Iron overload and liver dysfunction after allogeneic or autologous bone marrow transplantation.

Authors:  P J McKay; J A Murphy; S Cameron; A K Burnett; M Campbell; P Tansey; I M Franklin
Journal:  Bone Marrow Transplant       Date:  1996-01       Impact factor: 5.483

2.  Accidental busulfan overdose during conditioning for stem cell transplantation.

Authors:  A Jenke; J Freiberg-Richter; S Wilhelm; M Freund; U D Renner; M Bornhäuser; E Schleyer; G Ehninger; U Schuler
Journal:  Bone Marrow Transplant       Date:  2005-01       Impact factor: 5.483

3.  Role of oxidative stress and glutathione in busulfan toxicity in cultured murine hepatocytes.

Authors:  L D DeLeve; X Wang
Journal:  Pharmacology       Date:  2000-04       Impact factor: 2.547

4.  A population-based study of the biochemical and clinical expression of the H63D hemochromatosis mutation.

Authors:  Peter A Gochee; Lawrie W Powell; Digby J Cullen; Desiree Du Sart; Enrico Rossi; John K Olynyk
Journal:  Gastroenterology       Date:  2002-03       Impact factor: 22.682

Review 5.  New histopathologic findings in drug eruptions.

Authors:  J E Fitzpatrick
Journal:  Dermatol Clin       Date:  1992-01       Impact factor: 3.478

6.  Venocclusive disease of the liver after bone marrow transplantation: diagnosis, incidence, and predisposing factors.

Authors:  G B McDonald; P Sharma; D E Matthews; H M Shulman; E D Thomas
Journal:  Hepatology       Date:  1984 Jan-Feb       Impact factor: 17.425

Review 7.  The role of iron and reactive oxygen species in cell death.

Authors:  Scott J Dixon; Brent R Stockwell
Journal:  Nat Chem Biol       Date:  2014-01       Impact factor: 15.040

8.  The transferrin receptor modulates Hfe-dependent regulation of hepcidin expression.

Authors:  Paul J Schmidt; Paul T Toran; Anthony M Giannetti; Pamela J Bjorkman; Nancy C Andrews
Journal:  Cell Metab       Date:  2008-03       Impact factor: 27.287

9.  Hepatic veno-occlusive disease after bone marrow transplantation. Immunohistochemical identification of the material within occluded central venules.

Authors:  H M Shulman; A M Gown; D J Nugent
Journal:  Am J Pathol       Date:  1987-06       Impact factor: 4.307

10.  Severe hepatocellular injury after hematopoietic cell transplant: incidence, etiology and outcome.

Authors:  M Sakai; S I Strasser; H M Shulman; S J McDonald; H G Schoch; G B McDonald
Journal:  Bone Marrow Transplant       Date:  2009-03-23       Impact factor: 5.483

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.